ATE258182T1 - Verbindungen selektif-inhibitoren der t gamma 9 delta 2 lymphocyten - Google Patents

Verbindungen selektif-inhibitoren der t gamma 9 delta 2 lymphocyten

Info

Publication number
ATE258182T1
ATE258182T1 AT00917119T AT00917119T ATE258182T1 AT E258182 T1 ATE258182 T1 AT E258182T1 AT 00917119 T AT00917119 T AT 00917119T AT 00917119 T AT00917119 T AT 00917119T AT E258182 T1 ATE258182 T1 AT E258182T1
Authority
AT
Austria
Prior art keywords
lymphocytes
selective inhibitors
delta
gamma
compounds
Prior art date
Application number
AT00917119T
Other languages
English (en)
Inventor
Christian Belmant
Marc Bonneville
Marc Alix Peyrat
Jean-Jacques Fournie
Alan P Kozikowski
Original Assignee
Inst Nat Sante Rech Med
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Sangstat Medical Corp filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE258182T1 publication Critical patent/ATE258182T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/4028Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/4037Esters of poly(thio)phosphonic acids containing halogen or nitro(so) substituents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65502Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
    • C07F9/65505Phosphonic acids containing oxirane groups; esters thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT00917119T 1999-04-06 2000-04-04 Verbindungen selektif-inhibitoren der t gamma 9 delta 2 lymphocyten ATE258182T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904263A FR2791981B1 (fr) 1999-04-06 1999-04-06 Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
PCT/FR2000/000837 WO2000059916A1 (fr) 1999-04-06 2000-04-04 Composes inhibitant selectivement les lymphocytes t gamma 9 delta 2

Publications (1)

Publication Number Publication Date
ATE258182T1 true ATE258182T1 (de) 2004-02-15

Family

ID=9544056

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917119T ATE258182T1 (de) 1999-04-06 2000-04-04 Verbindungen selektif-inhibitoren der t gamma 9 delta 2 lymphocyten

Country Status (7)

Country Link
US (3) US6624151B1 (de)
EP (1) EP1165573B1 (de)
AT (1) ATE258182T1 (de)
AU (1) AU3823800A (de)
DE (1) DE60007847T2 (de)
FR (1) FR2791981B1 (de)
WO (1) WO2000059916A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
EP1426052B1 (de) * 2002-12-02 2009-09-02 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
US20100291118A1 (en) * 2003-12-02 2010-11-18 Innate Pharma Class of Gamma Delta T Cells Activators and Use Thereof
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
AU2006298677A1 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
CN109651429A (zh) * 2017-10-11 2019-04-19 清华大学 高效稳定的Vγ9Vδ2 T细胞的小分子激动剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications

Also Published As

Publication number Publication date
FR2791981A1 (fr) 2000-10-13
AU3823800A (en) 2000-10-23
US6624151B1 (en) 2003-09-23
EP1165573B1 (de) 2004-01-21
US20040006131A1 (en) 2004-01-08
DE60007847T2 (de) 2004-11-04
FR2791981B1 (fr) 2001-07-20
WO2000059916A1 (fr) 2000-10-12
DE60007847D1 (de) 2004-02-26
EP1165573A1 (de) 2002-01-02
US20040009123A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
EP1622616A4 (de) Hemmer der akt aktivität
EP1631548A4 (de) Hemmer der akt aktivität
EP1620411A4 (de) Hemmer der akt aktivität
UY27638A1 (es) Compuesto inhibidor de la hepatitis c
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DE60041584D1 (de) Substituierte oxoazaheterozyclische verbindungen
SE9904652D0 (sv) Novel Compounds
YU65802A (sh) Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
UY26899A1 (es) Derivados de pirazol fusionados
ATE400274T1 (de) Hemmstoffe der akt aktivität
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
WO2001092255A3 (en) Epothilone derivatives and methods for making and using the same
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
PA8495101A1 (es) Derivados de 13-metileritromicina
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ATE258182T1 (de) Verbindungen selektif-inhibitoren der t gamma 9 delta 2 lymphocyten
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
TW200505446A (en) Inhibitor of cox
ATE526323T1 (de) Die hiv-protease hemmende verbindungen
AR044175A1 (es) Compuestos de cefemo
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties